FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1910-1916 December 28, 2000 Number 26 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Fluorescence in situ hybridization has improved the detection of genomic aberrations in chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities in patients with chronic lymphocytic leukemia and assessed their prognostic implications.

Methods Mononuclear cells from the blood of 325 patients with chronic lymphocytic leukemia were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 6q21, 11q22–23, 13q14, and 17p13; trisomy of bands 3q26, 8q24, and 12q13; and translocations involving band 14q32. Molecular cytogenetic data were correlated with clinical findings.

Results Chromosomal aberrations were detected in 268 of 325 cases (82 percent). The most frequent changes were a deletion in 13q (55 percent), a deletion in 11q (18 percent), trisomy of 12q (16 percent), a deletion in 17p (7 percent), and a deletion in 6q (6 percent). Five categories were defined with a statistical model: 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality; the median survival times for patients in these groups were 32, 79, 114, 111, and 133 months, respectively. Patients in the 17p- and 11q-deletion groups had more advanced disease than those in the other three groups. Patients with 17p deletions had the shortest median treatment-free interval (9 months), and those with 13q deletions had the longest (92 months). In multivariate analysis, the presence or absence of a 17p deletion, the presence or absence of an 11q deletion, age, Binet stage, the serum lactate dehydrogenase level, and the white-cell count gave significant prognostic information.

Conclusions Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival. These findings have implications for the design of risk-adapted treatment strategies.

Source Information

From the Department of Internal Medicine III University of Ulm, Ulm (H.D., S.S., E.L., A.K., L.B., K.D., M.B.); and the Deutsches Krebsforschungszentrum, Heidelberg (A.B., P.L.) — both in Germany.

Address reprint requests to Dr. Hartmut Döhner at the Department of Internal Medicine III, University of Ulm, Robert-Koch-Str. 8, 89081 Ulm, Germany, or at hartmut.doehner{at}medizin.uni-ulm.de.

Full Text of this Article

This article has been cited by other articles:

• Loeder, S., Zenz, T., Schnaiter, A., Mertens, D., Winkler, D., Dohner, H., Debatin, K.-M., Stilgenbauer, S., Fulda, S. (2009). A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia. Cancer Res. 69: 8977-8986 [Abstract] [Full Text]  
• Calin, G. A., Croce, C. M. (2009). Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 114: 4761-4770 [Abstract] [Full Text]  
• Tam, C. S., Kantarjian, H., Cortes, J., Lynn, A., Pierce, S., Zhou, L., Keating, M. J., Thomas, D. A., Verstovsek, S. (2009). Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. JCO 27: 5587-5593 [Abstract] [Full Text]  
• Forconi, F., Sozzi, E., Cencini, E., Zaja, F., Intermesoli, T., Stelitano, C., Rigacci, L., Gherlinzoni, F., Cantaffa, R., Baraldi, A., Gallamini, A., Zaccaria, A., Pulsoni, A., Gobbi, M., Tassi, M., Raspadori, D., Leoncini, L., Rinaldi, A., Sabattini, E., Bertoni, F., Pileri, S. A., Lauria, F. (2009). Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 114: 4696-4702 [Abstract] [Full Text]  
• Friedman, D. R., Weinberg, J. B., Barry, W. T., Goodman, B. K., Volkheimer, A. D., Bond, K. M., Chen, Y., Jiang, N., Moore, J. O., Gockerman, J. P., Diehl, L. F., Decastro, C. M., Potti, A., Nevins, J. R. (2009). A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia. Clin. Cancer Res. 15: 6947-6955 [Abstract] [Full Text]  
• Eichhorst, B. F., Busch, R., Stilgenbauer, S., Stauch, M., Bergmann, M. A., Ritgen, M., Kranzhofer, N., Rohrberg, R., Soling, U., Burkhard, O., Westermann, A., Goede, V., Schweighofer, C. D., Fischer, K., Fink, A.-M., Wendtner, C. M., Brittinger, G., Dohner, H., Emmerich, B., Hallek, M., the German CLL Study Group (GCLLSG), (2009). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114: 3382-3391 [Abstract] [Full Text]  
• Pallasch, C. P., Patz, M., Park, Y. J., Hagist, S., Eggle, D., Claus, R., Debey-Pascher, S., Schulz, A., Frenzel, L. P., Claasen, J., Kutsch, N., Krause, G., Mayr, C., Rosenwald, A., Plass, C., Schultze, J. L., Hallek, M., Wendtner, C.-M. (2009). miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 114: 3255-3264 [Abstract] [Full Text]  
• Delgado, J., Milligan, D. W., Dreger, P. (2009). Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. Blood 114: 2581-2588 [Abstract] [Full Text]  
• Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H., Stilgenbauer, S. (2009). Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114: 2589-2597 [Abstract] [Full Text]  
• Bosch, F., Abrisqueta, P., Villamor, N., Terol, M. J., Gonzalez-Barca, E., Ferra, C., Gonzalez Diaz, M., Abella, E., Delgado, J., Carbonell, F., Garcia Marco, J. A., Escoda, L., Ferrer, S., Monzo, E., Gonzalez, Y., Estany, C., Jarque, I., Salamero, O., Muntanola, A., Montserrat, E. (2009). Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. JCO 27: 4578-4584 [Abstract] [Full Text]  
• Salerno, E., Scaglione, B. J., Coffman, F. D., Brown, B. D., Baccarini, A., Fernandes, H., Marti, G., Raveche, E. S. (2009). Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Molecular Cancer Therapeutics 8: 2684-2692 [Abstract] [Full Text]  
• Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R. F., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Hohloch, K., Soling, U., Schlag, R., Kneba, M., Hallek, M., Dohner, H. (2009). Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group. JCO 27: 3994-4001 [Abstract] [Full Text]  
• Alonso, R., Lopez-Guerra, M., Upshaw, R., Bantia, S., Smal, C., Bontemps, F., Manz, C., Mehrling, T., Villamor, N., Campo, E., Montserrat, E., Colomer, D. (2009). Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood 114: 1563-1575 [Abstract] [Full Text]  
• Steele, A. J., Prentice, A. G., Hoffbrand, A. V., Yogashangary, B. C., Hart, S. M., Lowdell, M. W., Samuel, E. R., North, J. M., Nacheva, E. P., Chanalaris, A., Kottaridis, P., Cwynarski, K., Wickremasinghe, R. G. (2009). 2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood 114: 1217-1225 [Abstract] [Full Text]  
• Tam, C. S., Shanafelt, T. D., Wierda, W. G., Abruzzo, L. V., Van Dyke, D. L., O'Brien, S., Ferrajoli, A., Lerner, S. A., Lynn, A., Kay, N. E., Keating, M. J. (2009). De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 114: 957-964 [Abstract] [Full Text]  
• ter Brugge, P. J., Ta, V. B. T., de Bruijn, M. J. W., Keijzers, G., Maas, A., van Gent, D. C., Hendriks, R. W. (2009). A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen. Blood 114: 119-127 [Abstract] [Full Text]  
• Hanlon, K., Ellard, S., Rudin, C. E., Thorne, S., Davies, T., Harries, L. W. (2009). Evaluation of 13q14 Status in Patients with Chronic Lymphocytic Leukemia Using Single Nucleotide Polymorphism-Based Techniques. J. Mol. Diagn. 11: 298-305 [Abstract] [Full Text]  
• Johnson, G. G., Sherrington, P. D., Carter, A., Lin, K., Liloglou, T., Field, J. K., Pettitt, A. R. (2009). A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene. Cancer Res. 69: 5210-5217 [Abstract] [Full Text]  
• Grove, C. S, Follows, G. A, Erber, W. N (2009). Incidental finding of lymphocytosis in an asymptomatic patient. BMJ 338: b2119-b2119 [Full Text]  
• Stamatopoulos, B., Haibe-Kains, B., Equeter, C., Meuleman, N., Soree, A., De Bruyn, C., Hanosset, D., Bron, D., Martiat, P., Lagneaux, L. (2009). Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. haematol 94: 790-799 [Abstract] [Full Text]  
• Stamatopoulos, B., Meuleman, N., Haibe-Kains, B., Saussoy, P., Van Den Neste, E., Michaux, L., Heimann, P., Martiat, P., Bron, D., Lagneaux, L. (2009). microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 113: 5237-5245 [Abstract] [Full Text]  
• Eichhorst, B., Hallek, M., Dreyling, M., On behalf of the ESMO Guidelines Working Group, (2009). Chronic lymphocytic leukemia: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv102-iv104 [Full Text]  
• Shanafelt, T. D., Kay, N. E., Jenkins, G., Call, T. G., Zent, C. S., Jelinek, D. F., Morice, W. G., Boysen, J., Zakko, L., Schwager, S., Slager, S. L., Hanson, C. A. (2009). B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 113: 4188-4196 [Abstract] [Full Text]  
• Tam, C. S., Abruzzo, L. V., Lin, K. I., Cortes, J., Lynn, A., Keating, M. J., Thomas, D. A., Pierce, S., Kantarjian, H., Verstovsek, S. (2009). The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 113: 4171-4178 [Abstract] [Full Text]  
• Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Buhler, A., Kienle, D., Winkler, D., Durig, J., van Oers, M. H. J., Mertens, D., Dohner, H., Stilgenbauer, S. (2009). miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113: 3801-3808 [Abstract] [Full Text]  
• Stros, M., Polanska, E., Struncova, S., Pospisilova, S. (2009). HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II{alpha}. Nucleic Acids Res 37: 2070-2086 [Abstract] [Full Text]  
• Hartmann, T. N., Grabovsky, V., Wang, W., Desch, P., Rubenzer, G., Wollner, S., Binsky, I., Vallon-Eberhard, A., Sapoznikov, A., Burger, M., Shachar, I., Haran, M., Honczarenko, M., Greil, R., Alon, R. (2009). Circulating B-Cell Chronic Lymphocytic Leukemia Cells Display Impaired Migration to Lymph Nodes and Bone Marrow. Cancer Res. 69: 3121-3130 [Abstract] [Full Text]  
• Hernandez, J. A., Rodriguez, A. E., Gonzalez, M., Benito, R., Fontanillo, C., Sandoval, V., Romero, M., Martin-Nunez, G., de Coca, A. G., Fisac, R., Galende, J., Recio, I., Ortuno, F., Garcia, J. L., de las Rivas, J., Gutierrez, N. C., San Miguel, J. F., Hernandez, J. M. (2009). A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. haematol 94: 364-371 [Abstract] [Full Text]  
• Hewamana, S., Lin, T. T., Rowntree, C., Karunanithi, K., Pratt, G., Hills, R., Fegan, C., Brennan, P., Pepper, C. (2009). Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia. JCO 27: 763-769 [Abstract] [Full Text]  
• Caligaris-Cappio, F. (2009). ROMA illuminates CLL genomic lesions. Blood 113: 1209-1210 [Full Text]  
• Grubor, V., Krasnitz, A., Troge, J. E., Meth, J. L., Lakshmi, B., Kendall, J. T., Yamrom, B., Alex, G., Pai, D., Navin, N., Hufnagel, L. A., Lee, Y.-H., Cook, K., Allen, S. L., Rai, K. R., Damle, R. N., Calissano, C., Chiorazzi, N., Wigler, M., Esposito, D. (2009). Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 113: 1294-1303 [Abstract] [Full Text]  
• Lamanna, N., Jurcic, J. G., Noy, A., Maslak, P., Gencarelli, A. N., Panageas, K. S., Heaney, M. L., Brentjens, R. J., Golde, D. W., Scheinberg, D. A., Zelenetz, A. D., Weiss, M. A. (2009). Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses. JCO 27: 491-497 [Abstract] [Full Text]  
• BOELENS, J., LUST, S., VANHOECKE, B., OFFNER, F. (2009). Chronic Lymphocytic Leukaemia. Anticancer Res 29: 605-615 [Abstract] [Full Text]  
• Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., Forconi, F., Lauria, F., Gaidano, G. (2009). The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness. Clin. Cancer Res. 15: 995-1004 [Abstract] [Full Text]  
• Lewintre, E. J., Martin, C. R., Ballesteros, C. G., Montaner, D., Rivera, R. F., Mayans, J. R., Garcia-Conde, J. (2009). Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia. haematol 94: 280-284 [Abstract] [Full Text]  
• Sargent, R., Jones, D., Abruzzo, L. V., Yao, H., Bonderover, J., Cisneros, M., Wierda, W. G., Keating, M. J., Luthra, R. (2009). Customized Oligonucleotide Array-Based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia. J. Mol. Diagn. 11: 25-34 [Abstract] [Full Text]  
• Kipps, T. J. (2009). Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy. Am Soc Clin Oncol Ed Book 2009: 385-393 [Abstract] [Full Text]  
• Hegde, G. V., Peterson, K. J., Emanuel, K., Mittal, A. K., Joshi, A. D., Dickinson, J. D., Kollessery, G. J., Bociek, R. G., Bierman, P., Vose, J. M., Weisenburger, D. D., Joshi, S. S. (2008). Hedgehog-Induced Survival of B-Cell Chronic Lymphocytic Leukemia Cells in a Stromal Cell Microenvironment: A Potential New Therapeutic Target. Mol Cancer Res 6: 1928-1936 [Abstract] [Full Text]  
• Vanura, K., Le, T., Esterbauer, H., Spath, F., Porpaczy, E., Shehata, M., Eigenberger, K., Hauswirth, A., Skrabs, C., Kromer, E., Schwarzinger, I., Streubel, B., Steininger, C., Fonatsch, C., Stilgenbauer, S., Wagner, O., Gaiger, A., Jager, U. (2008). Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. haematol 93: 1912-1916 [Abstract] [Full Text]  
• Fiegl, M., Erdel, M., Tinhofer, I., Hopfinger, G., Eigenberger, K., Falkner, F., Falkner, A., Brychtova, Y., Panovska, A., Doubek, M., Zabernigg, A., Sodia, S., Muhlberger, H., Fonatsch, C., Gastl, G., Mayer, J., Greil, R. (2008). Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories. ASH ANNUAL MEETING ABSTRACTS 112: 3164-3164 [Abstract]  
• Schetelig, J., van Biezen, A., Brand, R., Caballero, D., Martino, R., Itala, M., Garcia-Marco, J. A., Volin, L., Schmitz, N., Schwerdtfeger, R., Ganser, A., Onida, F., Mohr, B., Stilgenbauer, S., Bornhauser, M., de Witte, T., Dreger, P. (2008). Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis. JCO 26: 5094-5100 [Abstract] [Full Text]  
• Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maris, M., Shizuru, J., Maziarz, R., Agura, E., Chauncey, T. R., Pulsipher, M. A., McSweeney, P. A., Wade, J. C., Bruno, B., Langston, A., Radich, J., Niederwieser, D., Blume, K. G., Storb, R., Maloney, D. G. (2008). Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. JCO 26: 4912-4920 [Abstract] [Full Text]  
• Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwanen, C., Dohner, H., Stilgenbauer, S. (2008). Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112: 3322-3329 [Abstract] [Full Text]  
• Hartel, P. H., Shackelford, A. L., Hartel, J. V., Wenger, S. L. (2008). Del(5q) Is Associated With Clinical and Histological Parameters in Small Cell Neuroendocrine Lung Carcinoma. INT J SURG PATHOL 16: 419-423 [Abstract]  
• Rossi, D., Zucchetto, A., Rossi, F. M., Capello, D., Cerri, M., Deambrogi, C., Cresta, S., Rasi, S., De Paoli, L., Bodoni, C. L., Bulian, P., Del Poeta, G., Ladetto, M., Gattei, V., Gaidano, G. (2008). CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. haematol 93: 1575-1579 [Abstract] [Full Text]  
• Caligaris-Cappio, F., Ghia, P. (2008). Novel Insights in Chronic Lymphocytic Leukemia: Are We Getting Closer to Understanding the Pathogenesis of the Disease?. JCO 26: 4497-4503 [Abstract] [Full Text]  
• Gunn, S. R., Mohammed, M. S., Gorre, M. E., Cotter, P. D., Kim, J., Bahler, D. W., Preobrazhensky, S. N., Higgins, R. A., Bolla, A. R., Ismail, S. H., de Jong, D., Eldering, E., van Oers, M. H.J., Mellink, C. H.M., Keating, M. J., Schlette, E. J., Abruzzo, L. V., Robetorye, R. S. (2008). Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia. J. Mol. Diagn. 10: 442-451 [Abstract] [Full Text]  
• Kipps, T. J. (2008). Genomic complexity in chronic lymphocytic leukemia. Blood 112: 1550-1550 [Full Text]  
• Kujawski, L., Ouillette, P., Erba, H., Saddler, C., Jakubowiak, A., Kaminski, M., Shedden, K., Malek, S. N. (2008). Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 112: 1993-2003 [Abstract] [Full Text]  
• Tam, C. S., Nussenzveig, R. M., Popat, U., Bueso-Ramos, C. E., Thomas, D. A., Cortes, J. A., Champlin, R. E., Ciurea, S. E., Manshouri, T., Pierce, S. M., Kantarjian, H. M., Verstovsek, S. (2008). The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 112: 1628-1637 [Abstract] [Full Text]  
• Tam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D. A., Cortes, J., Lerner, S., Keating, M. J. (2008). Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112: 975-980 [Abstract] [Full Text]  
• Frohling, S., Dohner, H. (2008). Chromosomal Abnormalities in Cancer. NEJM 359: 722-734 [Full Text]  
• Rawstron, A. C., Bennett, F. L., O'Connor, S. J.M., Kwok, M., Fenton, J. A.L., Plummer, M., de Tute, R., Owen, R. G., Richards, S. J., Jack, A. S., Hillmen, P. (2008). Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. NEJM 359: 575-583 [Abstract] [Full Text]  
• Dighiero, G. (2008). Monoclonal B-Cell Lymphocytosis -- A Frequent Premalignant Condition. NEJM 359: 638-640 [Full Text]  
• Guarini, A., Chiaretti, S., Tavolaro, S., Maggio, R., Peragine, N., Citarella, F., Ricciardi, M. R., Santangelo, S., Marinelli, M., De Propris, M. S., Messina, M., Mauro, F. R., Del Giudice, I., Foa, R. (2008). BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. Blood 112: 782-792 [Abstract] [Full Text]  
• Zenz, T., Habe, S., Benner, A., Kienle, D., Dohner, H., Stilgenbauer, S. (2008). The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. haematol 93: 1111-1113 [Full Text]  
• Willmore, E., Elliott, S. L., Mainou-Fowler, T., Summerfield, G. P., Jackson, G. H., O'Neill, F., Lowe, C., Carter, A., Harris, R., Pettitt, A. R., Cano-Soumillac, C., Griffin, R. J., Cowell, I. G., Austin, C. A., Durkacz, B. W. (2008). DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia. Clin. Cancer Res. 14: 3984-3992 [Abstract] [Full Text]  
• Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., Kipps, T. J. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456 [Abstract] [Full Text]  
• Aydin, S., Rossi, D., Bergui, L., D'Arena, G., Ferrero, E., Bonello, L., Omede, P., Novero, D., Morabito, F., Carbone, A., Gaidano, G., Malavasi, F., Deaglio, S. (2008). CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?. Blood 111: 5646-5653 [Abstract] [Full Text]  
• Quijano, S., Lopez, A., Rasillo, A., Barrena, S., Luz Sanchez, M., Flores, J., Fernandez, C., Sayagues, J. M., Osuna, C. S., Fernandez, N., Gonzalez, M., Giraldo, P., Giralt, M., Perez, M. C., Martin-Antoran, J. M., Gutierrez, O., Perdiguer, L., Diaz Mediavilla, J., Gonzalez Silva, M., Asensio del Rio, A., Cervero, C., Guerra, J. L., Butron, R., del Carmen Garcia, M., Almeida, J., Orfao, A. (2008). Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood 111: 5130-5141 [Abstract] [Full Text]  
• Shanafelt, T. D., Hanson, C., Dewald, G. W., Witzig, T. E., LaPlant, B., Abrahamzon, J., Jelinek, D. F., Kay, N. E. (2008). Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression. JCO 26: e5-e6 [Full Text]  
• Sander, S., Bullinger, L., Leupolt, E., Benner, A., Kienle, D., Katzenberger, T., Kalla, J., Ott, G., Muller-Hermelink, H. K., Barth, T. F.E., Moller, P., Lichter, P., Dohner, H., Stilgenbauer, S. (2008). Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. haematol 93: 680-687 [Abstract] [Full Text]  
• Hewamana, S., Alghazal, S., Lin, T. T., Clement, M., Jenkins, C., Guzman, M. L., Jordan, C. T., Neelakantan, S., Crooks, P. A., Burnett, A. K., Pratt, G., Fegan, C., Rowntree, C., Brennan, P., Pepper, C. (2008). The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111: 4681-4689 [Abstract] [Full Text]  
• Athanasiadou, A., Stamatopoulos, K., Gaitatzi, M., Stavroyianni, N., Fassas, A., Anagnostopoulos, A. (2008). Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. haematol 93: 473-474 [Abstract] [Full Text]  
• Agrawal, S. G., Liu, F.-T., Wiseman, C., Shirali, S., Liu, H., Lillington, D., Du, M.-Q., Syndercombe-Court, D., Newland, A. C., Gribben, J. G., Jia, L. (2008). Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood 111: 2790-2796 [Abstract] [Full Text]  
• Ouillette, P., Erba, H., Kujawski, L., Kaminski, M., Shedden, K., Malek, S. N. (2008). Integrated Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Subtypes of Deletion 13q14. Cancer Res. 68: 1012-1021 [Abstract] [Full Text]  
• Roos, G., Krober, A., Grabowski, P., Kienle, D., Buhler, A., Dohner, H., Rosenquist, R., Stilgenbauer, S. (2008). Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 111: 2246-2252 [Abstract] [Full Text]  
• Gachard, N., Salviat, A., Boutet, C., Arnoulet, C., Durrieu, F., Lenormand, B., Lepretre, S., Olschwang, S., Jardin, F., Lafage-Pochitaloff, M., Penther, D., Sainty, D., Reminieras, L., Feuillard, J., Bene, M. C., for the GEIL, (2008). Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. haematol 93: 215-223 [Abstract] [Full Text]  
• Saddler, C., Ouillette, P., Kujawski, L., Shangary, S., Talpaz, M., Kaminski, M., Erba, H., Shedden, K., Wang, S., Malek, S. N. (2008). Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111: 1584-1593 [Abstract] [Full Text]  
• Sellick, G. S., Wade, R., Richards, S., Oscier, D. G., Catovsky, D., Houlston, R. S. (2008). Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood 111: 1625-1633 [Abstract] [Full Text]  
• Gattei, V., Bulian, P., Del Principe, M. I., Zucchetto, A., Maurillo, L., Buccisano, F., Bomben, R., Dal-Bo, M., Luciano, F., Rossi, F. M., Degan, M., Amadori, S., Del Poeta, G. (2008). Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111: 865-873 [Abstract] [Full Text]  
• Hauswirth, A. W., Jager, U. (2008). Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia. haematol 93: 14-19 [Full Text]  
• Gine, E., Crespo, M., Muntanola, A., Calpe, E., Baptista, M. J., Villamor, N., Montserrat, E., Bosch, F. (2008). Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. haematol 93: 75-82 [Abstract] [Full Text]  
• Bosch, F., Ferrer, A., Villamor, N., Gonzalez, M., Briones, J., Gonzalez-Barca, E., Abella, E., Gardella, S., Escoda, L., Perez-Ceballos, E., Asensi, A., Sayas, M. J., Font, L., Altes, A., Muntanola, A., Bertazzoni, P., Rozman, M., Aymerich, M., Gine, E., Montserrat, E. (2008). Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. Clin. Cancer Res. 14: 155-161 [Abstract] [Full Text]  
• Gribben, J. G. (2008). Molecular Profiling in CLL. ASH Education Book 2008: 444-449 [Abstract] [Full Text]  
• Gribben, J. G. (2008). The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia. Am Soc Clin Oncol Ed Book 2008: 291-296 [Abstract] [Full Text]  
• Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C., Mayer, J. (2007). Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. JCO 25: 5616-5623 [Abstract] [Full Text]  
• Austen, B., Skowronska, A., Baker, C., Powell, J. E., Gardiner, A., Oscier, D., Majid, A., Dyer, M., Siebert, R., Taylor, A. M., Moss, P. A., Stankovic, T. (2007). Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion. JCO 25: 5448-5457 [Abstract] [Full Text]  
• Santidrian, A. F., Cosialls, A. M., Coll-Mulet, L., Iglesias-Serret, D., de Frias, M., Gonzalez-Girones, D. M., Campas, C., Domingo, A., Pons, G., Gil, J. (2007). The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells. haematol 92: 1631-1638 [Abstract] [Full Text]  
• Damle, R. N., Temburni, S., Calissano, C., Yancopoulos, S., Banapour, T., Sison, C., Allen, S. L., Rai, K. R., Chiorazzi, N. (2007). CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110: 3352-3359 [Abstract] [Full Text]  
• Tsimberidou, A. M., Wen, S., O'Brien, S., McLaughlin, P., Wierda, W. G., Ferrajoli, A., Faderl, S., Manning, J., Lerner, S., Mai, C. V., Rodriguez, A. M., Hess, M., Do, K.-A., Freireich, E. J., Kantarjian, H. M., Medeiros, L. J., Keating, M. J. (2007). Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center. JCO 25: 4648-4656 [Abstract] [Full Text]  
• Willimott, S., Baou, M., Huf, S., Deaglio, S., Wagner, S. D. (2007). Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. haematol 92: 1359-1366 [Abstract] [Full Text]  
• Durig, J., Ebeling, P., Grabellus, F., Sorg, U. R., Mollmann, M., Schutt, P., Gothert, J., Sellmann, L., Seeber, S., Flasshove, M., Duhrsen, U., Moritz, T. (2007). A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease. Cancer Res. 67: 8653-8661 [Abstract] [Full Text]  
• Joshi, A. D., Hegde, G. V., Dickinson, J. D., Mittal, A. K., Lynch, J. C., Eudy, J. D., Armitage, J. O., Bierman, P. J., Bociek, R. G., Devetten, M. P., Vose, J. M., Joshi, S. S. (2007). ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38 Expressing B-Cell Chronic Lymphocytic Leukemia. Clin. Cancer Res. 13: 5295-5304 [Abstract] [Full Text]  
• Stilgenbauer, S., Sander, S., Bullinger, L., Benner, A., Leupolt, E., Winkler, D., Krober, A., Kienle, D., Lichter, P., Dohner, H. (2007). Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. haematol 92: 1242-1245 [Abstract] [Full Text]  
• Ross, C. W., Ouillette, P. D., Saddler, C. M., Shedden, K. A., Malek, S. N. (2007). Comprehensive Analysis of Copy Number and Allele Status Identifies Multiple Chromosome Defects Underlying Follicular Lymphoma Pathogenesis. Clin. Cancer Res. 13: 4777-4785 [Abstract] [Full Text]  
• Kienle, D., Katzenberger, T., Ott, G., Saupe, D., Benner, A., Kohlhammer, H., Barth, T. F.E., Holler, S., Kalla, J., Rosenwald, A., Muller-Hermelink, H. K., Moller, P., Lichter, P., Dohner, H., Stilgenbauer, S. (2007). Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors. JCO 25: 2770-2777 [Abstract] [Full Text]  
• Raveche, E. S., Salerno, E., Scaglione, B. J., Manohar, V., Abbasi, F., Lin, Y.-C., Fredrickson, T., Landgraf, P., Ramachandra, S., Huppi, K., Toro, J. R., Zenger, V. E., Metcalf, R. A., Marti, G. E. (2007). Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109: 5079-5086 [Abstract] [Full Text]  
• Sabattini, E., Orduz, R., Campidelli, C., Zinzani, P. L., Callea, V., Zupo, S., Cutrona, G., Morabito, F., Ferrarini, M., Pileri, S. (2007). B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. J. Clin. Pathol. 60: 627-632 [Abstract] [Full Text]  
• Josefsson, P., Geisler, C. H., Leffers, H., Petersen, J. H., Andersen, M. K., Jurlander, J., Buhl, A. M. (2007). CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 109: 4973-4979 [Abstract] [Full Text]  
• Wierda, W. G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.-A., Cortes, J., Thomas, D., Garcia-Manero, G., Koller, C., Beran, M., Giles, F., Ravandi, F., Lerner, S., Kantarjian, H., Keating, M. (2007). Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109: 4679-4685 [Abstract] [Full Text]  
• Fulci, V., Chiaretti, S., Goldoni, M., Azzalin, G., Carucci, N., Tavolaro, S., Castellano, L., Magrelli, A., Citarella, F., Messina, M., Maggio, R., Peragine, N., Santangelo, S., Mauro, F. R., Landgraf, P., Tuschl, T., Weir, D. B., Chien, M., Russo, J. J., Ju, J., Sheridan, R., Sander, C., Zavolan, M., Guarini, A., Foa, R., Macino, G. (2007). Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109: 4944-4951 [Abstract] [Full Text]  
• Vallat, L. D., Park, Y., Li, C., Gribben, J. G. (2007). Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood 109: 3989-3997 [Abstract] [Full Text]  
• Muntanola, A., Bosch, F., Arguis, P., Arellano-Rodrigo, E., Ayuso, C., Gine, E., Crespo, M., Abrisqueta, P., Moreno, C., Cobo, F., Lopez-Guillermo, A., Montserrat, E. (2007). Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic Leukemia. JCO 25: 1576-1580 [Abstract] [Full Text]  
• Wolff, D. J., Bagg, A., Cooley, L. D., Dewald, G. W., Hirsch, B. A., Jacky, P. B., Rao, K. W., Rao, P. N., the Association for Molecular Pathology Clinical P, (2007). Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders. J. Mol. Diagn. 9: 134-143 [Abstract] [Full Text]